SCLX
Scilex Holding Company
$10.58
+0.06
(+0.57%)
Mkt Cap
89.84M
Volume
137,784
52W Range
3.92-34.27
Sector
Healthcare
Beta
1.42
EPS (TTM)
-34.85
P/E Ratio
-0.38
Revenue (TTM)
30.25M
Rev Growth (5Y)
+5.1%
EPS Growth (5Y)
N/A
Company Description
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 30.25M | 56.59M | 46.74M | 38.03M | 31.32M | 23.56M | 21.03M |
| Net Income | (358.73M) | (72.81M) | (114.33M) | (23.36M) | (88.42M) | (47.52M) | (178.59M) |
| EPS | -36.48 | -19.43 | -44.85 | -6.09 | -23.29 | -0.01 | -1.27 |
| Free Cash Flow | 3.68M | 19.35M | (21.04M) | (23.32M) | (28.66M) | (31.49M) | (61.01M) |
| FCF / Share | 0.33 | 2.78 | -5.65 | -6.08 | -7.55 | -7.81 | -15.13 |
| Operating CF | 3.82M | 19.35M | (20.71M) | (21.26M) | (28.66M) | (31.46M) | (60.42M) |
| Total Assets | 364.98M | 92.95M | 101.31M | 86.53M | 77.93M | 81.50M | N/A |
| Total Debt | 132.54M | 37.96M | 128.46M | 1.41M | 154.75M | 138.63M | N/A |
| Cash & Equiv | 4.96M | 3.27M | 3.92M | 2.18M | 4.34M | 4.84M | N/A |
| Book Value | (207.78M) | (192.64M) | (172.94M) | 36.24M | (223.88M) | (141.68M) | N/A |
| Return on Equity | N/A | N/A | N/A | -0.64 | N/A | N/A | N/A |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.79M | 10.56M | 9.90M | 5.00M | 14.90M | 14.44M | 16.37M | 10.88M | 13.46M | 10.12M | 12.58M | 10.58M |
| Net Income | (33.11M) | (257.23M) | (86.06M) | (26.08M) | (6.46M) | (4.39M) | (37.58M) | (24.38M) | (21.40M) | (35.53M) | (26.65M) | (30.75M) |
| EPS | -3.00 | -22.17 | -7.42 | -2.26 | -1.23 | -1.21 | -10.94 | -6.69 | -7.49 | -8.89 | -0.19 | -0.22 |
| Free Cash Flow | (18.01M) | 8.53M | 7.05M | 5.86M | 2.38M | 4.96M | 2.16M | 9.24M | (5.67M) | 5.75M | (13.48M) | (7.74M) |
| FCF / Share | -1.63 | 0.74 | 0.61 | 0.51 | 0.34 | 1.37 | 0.63 | 2.53 | -1.47 | 1.44 | -3.31 | -1.94 |
| Operating CF | (17.88M) | 8.23M | 7.05M | 6.01M | 2.53M | 5.11M | 2.31M | 9.39M | (5.37M) | 5.90M | (13.47M) | (7.74M) |
| Total Assets | 364.98M | 275.88M | 83.75M | 78.98M | 92.95M | 100.43M | 104.54M | 91.24M | 101.31M | 80.53M | 126.46M | 86.05M |
| Total Debt | 132.54M | 67.67M | 41.77M | 41.51M | 37.96M | 101.37M | 107.00M | 112.05M | 128.46M | 125.34M | 37.73M | 10.83M |
| Cash & Equiv | 4.96M | 878,000 | 4.10M | 5.80M | 3.27M | 77,000 | 6.89M | 1.82M | 3.92M | 1.95M | 34.12M | 5.07M |
| Book Value | (207.78M) | (176.94M) | (248.99M) | (211.48M) | (192.64M) | (211.32M) | (214.69M) | (189.79M) | (172.94M) | (162.67M) | 10.42M | 11.08M |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.56 | -2.78 |
SCLX News
Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026
Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform
Datavault AI Announces Execution of Binding Term Sheet for $120 Million Cash Contribution From Scilex Holding Company to Fund 100-City GPU Expansion of Quantum-Ready SanQtum Platform
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd.
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026
Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
Scilex (NASDAQ:SCLX) Trading Up 8.8% – Time to Buy?